The worldwide idiopathic thrombocytopenic purpura therapeutics market is projected to attain nearly USD 566 million by 2020. It can expand at a 5.9 % CAGR over the forecast period (2014-2020). The market stood at around USD 382 million in 2013. It is driven by favorable government policies such as the U.S. Orphan Drug Act. Demand of combination therapies like dexamethasone and TPO-RA is another factor which may influence market growth.
ITP (idiopathic thrombocytopenic purpura) is a rare disease with low affliction rates. This disease leads to excessive bruising or bleeding due to the lack of blood platelets. It is also known as immune thrombocytopenia and can affect children and adults alike. ITP affects nearly 0.3% out of every 100,000 in the U.S. Commercialization of new drugs like IVIG3I 10% and Avatrombopag is anticipated to propel demand over the forecast period.
For Market Research Report on “Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market” Visit - https://www.hexaresearch.com/research-report/idiopathic-thrombocytopenic-purpura-itp-therapeutics-industry
The global Idiopathic Thrombocytopenic Purpura Therapeutics Market is segmented according to products and regions. As per products, the classifications are TPO-RA (thrombopoetin receptor agonist), anti-D immunoglobulin, intravenous immunoglobulin (IVIG), anti-D immunoglobulins, corticosteroids, and others. Corticosteroids were valued over USD 125 million in 2013 and are the most widely preferred drug for treating ITP. Its high share in overall revenues can be attributed to its low price. TPO-RA can experience surging demand on account of commercialization of Avatrombopag. This can be attributed to the use of TPO-RA in splenectomized patients suffering relapses. Avatrombopag can act as a second line of defense due to its positive clinical trial results.
High response rates displayed by patients administered with Eltrombopag and Romiplostim can positively impact the TPO-RA segment till 2020. Other therapeutic classes are interferon, immunosuppressant, and monoclonal antibodies (mAbs). mAbs such as Rituximab were used frequently in Europe till 2013. However, patent expiry of the same has created scope for drug manufacturers to develop biosimilars.
North America, Europe, Asia Pacific, and RoW (Rest of the World) are regional segments of the worldwide ITP market. North America led the overall industry in 2013 owing to favorable government initiatives, rising ITP cases, and high research funding. Clinical trials based on combination therapy and drug developments are expected to spur regional demand over the forecast period. North America had a revenue share exceeding 40% in 2013.
Europe was the second largest market in 2013 propelled by high product penetration and favorable initiatives pertaining to its production. Asia Pacific is expected to prosper considerably over the next 6 years due to the untapped markets in India and China. Furthermore, sophisticated healthcare and government initiatives in Australia and Japan can contribute significantly to regional demand.
Notable players of the Idiopathic Thrombocytopenic Purpura Therapeutics Market are Grifols Biologicals Inc.; GlaxoSmithKline (GSK) Plc; Amgen Inc.; and F. Hoffman-La Roche AG. These companies invest robustly in research and development to launch newer products in order to sustain their respective market shares.
GSK recently got approval for its trademark product “Revolade™” by Health Canada, the department of the government of Canada that looks into national public health. This product is a capsule which needs to be taken orally to treat ITP. It can help boost production of blood platelets. Amgen Inc.’s “Nplate” helps restore blood platelets in children. It can act as a viable alternative to treat severe bleeding concurrent with ITP. This drug had generated nearly USD 400 million in 2013. Although Promacta and Nplate received approvals at the same time, the former is expected to dominate the market in the near future.